Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 9/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.36 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7234454 | 1.00 | ALDH1A1 (0.47) | ALDH1A1APAF1PTPN1IDO1SOAT1 | |
| SCHEMBL4300496 | 1.00 | ALDH1A1 (0.47) | ALDH1A1APAF1PTPN1IDO1SOAT1 | |
| SCHEMBL20230447 | 0.78 | ALDH1A1 (0.40) | ALDH1A1APAF1PTPN1SOAT1S100A4 | |
| SCHEMBL20230420 | 0.74 | ALDH1A1 (0.43) | ALDH1A1APAF1PTPN1IDO1SOAT1 | |
| Anthraquinone SCHEMBL27601272 | 0.65 | MEN1 (0.63) | ALDH1A1APAF1PTPN1SOAT1S100A4 | |
| Anthraquinone SCHEMBL27605254 | 0.63 | PTPN1 (0.61) | ALDH1A1APAF1PTPN1SOAT1S100A4 | |
| SCHEMBL14342825 | 0.63 | ALDH1A1 (0.49) | ALDH1A1APAF1IDO1MAPTKDM4E | |
| SCHEMBL21814444 | 0.63 | ALDH1A1 (0.79) | ALDH1A1APAF1PTPN1SOAT1S100A4 | |
| SCHEMBL30587685 | 0.63 | ALDH1A1 (0.79) | ALDH1A1APAF1PTPN1SOAT1S100A4 | |
| SCHEMBL13875721 | 0.62 | GRIN1 (0.67) | ALDH1A1MAPTHPGDTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | ALDH1A1 1045/4885APAF1 974/4885PTPN1 3701/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | ALDH1A1 1038/4885APAF1 730/4885PTPN1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.